LONDON (dpa-AFX) - Positive results from the primary analysis of the ongoing
DESTINY-PanTumor02 Phase II trial showed that Enhertu (fam-trastuzumab
deruxtecan-nxki) continued to demonstrate clinically meaningful and durable
responses, leading to a clinically meaningful survival benefit in previously
treated patients across multiple HER2-expressing advanced solid tumors,
AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said in a statement.

Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC)
being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The companies noted that Enhertu showed a median progression-free survival of
6.9 months and median overall survival of 13.4 months in the overall trial
population.

According to the companies, the results reaffirm potential role of Enhertu as a
tumor-agnostic therapy for previously treated patients with HER2-expressing
solid tumors and support ongoing discussions with global regulatory authorities.

For More Such Health News, visit rttnews.com



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX